Acrivon Therapeutics (ACRV) announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation, BDD, for the ACR-368 OncoSignature assay, a multiplex immunofluorescence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback